GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cara Therapeutics Inc (FRA:69C0) » Definitions » Cash Receipts from Loans

Cara Therapeutics (FRA:69C0) Cash Receipts from Loans


View and export this data going back to 2014. Start your Free Trial

What is Cara Therapeutics Cash Receipts from Loans?

Cash Receipts from Loans only applicable to companies reporting Cash Flow from Operations in direct method.


Cara Therapeutics Business Description

Traded in Other Exchanges
Address
400 Atlantic Street, Suite 500, Stamford, CT, USA, 06901
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.